Easywell Biomedicals (ROCO:1799) Cyclically Adjusted FCF per Share: NT$-2.72 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1799 Easywell Biomedicals Inc ROCO:1799
54 GF Score
Price NT$32.05
GF Value NT$82.98
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Easywell Biomedicals Cyclically Adjusted FCF per Share?

Easywell Biomedicals ROCO:1799 -0.47% 54 Cyclically Adjusted FCF per Share is NT$-2.72 as of Mar. 2026. GuruFocus rates ROCO:1799 with a GF Score™ of 54/100 and a GF Value™ of NT$82.98 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Easywell Biomedicals's adjusted free cash flow per share for the three months ended in Mar. 2026 was NT$0.623. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is NT$-2.72 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 12.10% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Easywell Biomedicals was 12.10% per year. The lowest was 0.80% per year. And the median was 4.45% per year.

As of today (2026-08-04), Easywell Biomedicals's current stock price is NT$32.05. Easywell Biomedicals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was NT$-2.72. Easywell Biomedicals's Cyclically Adjusted Price-to-FCF of today is .


Easywell Biomedicals  (ROCO:1799) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Easywell Biomedicals Cyclically Adjusted FCF per Share Related Terms


Easywell Biomedicals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Easywell Biomedicals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Easywell Biomedicals Cyclically Adjusted FCF per Share Chart

Easywell Biomedicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.51 -4.32 -4.10 -3.74 -2.93

Easywell Biomedicals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.71 -3.54 -3.29 -2.93 -2.72

ROCO:1799 vs ZTS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Easywell Biomedicals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Easywell Biomedicals Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Easywell Biomedicals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Easywell Biomedicals's Cyclically Adjusted Price-to-FCF falls into.


ROCO:1799
54GF Score
Easywell Biomedicals Inc ROCO:1799
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Easywell Biomedicals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Easywell Biomedicals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.623/330.2130*330.2130
=0.623

Current CPI (Mar. 2026) = 330.2130.

Easywell Biomedicals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -1.692 241.018 -2.318
201609 -1.954 241.428 -2.673
201612 -0.804 241.432 -1.100
201703 -1.238 243.801 -1.677
201706 -1.415 244.955 -1.907
201709 -1.345 246.819 -1.799
201712 -0.975 246.524 -1.306
201803 -1.344 249.554 -1.778
201806 -1.232 251.989 -1.614
201809 -0.197 252.439 -0.258
201812 -1.234 251.233 -1.622
201903 -0.683 254.202 -0.887
201906 -0.834 256.143 -1.075
201909 -0.269 256.759 -0.346
201912 -0.647 256.974 -0.831
202003 -0.625 258.115 -0.800
202006 -0.227 257.797 -0.291
202009 -0.608 260.280 -0.771
202012 -0.394 260.474 -0.499
202103 -0.423 264.877 -0.527
202106 -0.006 271.696 -0.007
202109 -0.555 274.310 -0.668
202112 -0.254 278.802 -0.301
202203 -0.051 287.504 -0.059
202206 -0.132 296.311 -0.147
202209 -0.194 296.808 -0.216
202212 -0.156 296.797 -0.174
202303 -0.197 301.836 -0.216
202306 -0.269 305.109 -0.291
202309 -0.447 307.789 -0.480
202312 -0.568 306.746 -0.611
202403 -0.225 312.332 -0.238
202406 -0.641 314.175 -0.674
202409 0.032 315.301 0.034
202412 -0.588 315.605 -0.615
202503 0.325 319.799 0.336
202506 0.028 322.561 0.029
202509 0.329 324.800 0.334
202512 0.206 324.054 0.210
202603 0.623 330.213 0.623

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of NT$-2.72 mean?
Easywell Biomedicals (ROCO:1799) has a Cyclically Adjusted FCF per Share of NT$-2.72 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Easywell Biomedicals and its competitors.
Is Easywell Biomedicals' Cyclically Adjusted FCF per Share too high?
Easywell Biomedicals' current Cyclically Adjusted FCF per Share is NT$-2.72. Overall, Easywell Biomedicals has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' Cyclically Adjusted FCF per Share compare to ZTS?
Easywell Biomedicals' Cyclically Adjusted FCF per Share of NT$-2.72 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Easywell Biomedicals and its competitors. Easywell Biomedicals's current Cyclically Adjusted FCF per Share is NT$-2.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$82.98, compared to a current price of NT$32.05 — trading 61.4% below its estimated fair value. The current Cyclically Adjusted FCF per Share is NT$-2.72. Easywell Biomedicals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current Cyclically Adjusted FCF per Share is NT$-2.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?

Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued. The current stock price of NT$32.05 is trading 61.4% below its estimated GF Value™ of NT$82.98. GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.

Key valuation signals for ROCO:1799:

  • Cyclically Adjusted FCF per Share: NT$-2.72
  • GF Value™: NT$82.98 vs. price of NT$32.05 (61.4% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Easywell Biomedicals Business Description

Address No.10, Yanfa 2nd Road, Hsinchu Science Park, 1st floor, Hsinchu, TWN, 30076
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
54GF Score

Get the complete analysis for ROCO:1799

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.05
Price
NT$82.98
GF Value